drugset / Trial / NCT05814809

Clinical Trial to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers

NCT05814809

Phase 1 Completed 30 enrolled Onconic Therapeutics Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate the safety and the pharmacokinetics of the JP-1366 20 mg tablet and capsule oral administration in healthy adult volunteers.

Timeline

Start
2022-09-30
Primary completion
2022-10-09
Completion
2022-11-09

Drugs

EvaluationDrugModalityDoseRoute
Subject JP-1366 Unknown 20 mg Oral

Indications

No indication recorded.